International prevalence of recurrent wheezing during the first year of life: variability, treatment patterns and use of health resources

Javier Mallol,1 Luis García-Marcos,2 Dirceu Solé,3 Paul Brand,4 the EISL Study Group

ABSTRACT

Background Recurrent wheezing (RW) during the first year of life is a major cause of respiratory morbidity worldwide, yet there are no studies on its prevalence at an international level. A study was undertaken to determine the prevalence of RW in infants during their first year of life in affluent and non-affluent localities.

Methods This international population-based study was performed in random samples of infants aged 12–15 months from 17 centres in Latin America and Europe. It uses a validated questionnaire answered by parents at the primary care health clinics where infants attend for growth/development monitoring and/or vaccine administration.

Results Among the 30,093 infants surveyed, 45.2% (95% CI 44.7% to 45.8%) had at least one episode of wheezing and 20.3% (95% CI 19.8% to 20.7%) had RW. The mean prevalence of RW in Latin American and European centres was 21.4% (95% CI 20.9% to 21.9%) and 15.0% (95% CI 14.0% to 15.9%), respectively (p<0.001). There was significant morbidity associated with RW in terms of severe episodes (59.4%), visits to the emergency department (71.1%) and hospital admissions (26.8%); 46.1% used inhaled corticosteroids.

Conclusions The prevalence of RW in infants during the first year of life is high and varies between localities. A significant proportion of infants progress to a more severe condition which results in high use of health resources (visits to emergency department and hospitalisations). The prevalence of RW is lower and less severe in European than in Latin American centres, suggesting there is a higher risk for the disease in developing areas.

INTRODUCTION

Despite the fact that recurrent wheezing (RW) in the first year of life—defined as three or more episodes of wheezing during that time—and its associated morbidity is a significant global public health problem, there is no international information on its prevalence and severity obtained from the general population with standardised methods and including centres in both high- and low-income countries. It is well recognised that RW in infants significantly affects the quality of life of patients and their families and represents an important cause for using healthcare resources, thus resulting in a large health economic impact.3 4 In a prevalence study in young children aged 1–5 years from the USA and Europe, it was found that one-third of them suffered from recurrent asthma-like symptoms.4 Similarly, a high prevalence of RW has been found in the UK among preschool children aged 1–4 years. In that study, the prevalence of current wheezing (one or more episodes) in 1-year-old children was 25.5% in South Asians and 55.6% in white infants.5

The prevalence of wheezing in the first year of life seems to be higher in developing countries, as found in a birth cohort study from Latin America undertaken in a low socioeconomic urban population.6 Although the prevalence of RW in infants might be increased in low-resourced populations,6–8 to the best of our knowledge there is no comparative information which includes infants from different centres in both developing and developed countries.

The hypothesis of the Estudio Internacional de Sibilancias en Lactantes (EISL) study (or International Study of Wheezing in Infants) is that the prevalence of RW during the first year of life is as variable as the prevalence of asthma symptoms in older children,9 10 and differs between affluent and non-affluent countries. Here we describe the findings of the aforementioned study, which was performed with a standardised methodology and a validated questionnaire11,12 across different centres in Latin America and Europe.

METHODS

The EISL is a multicountry multicentric cross-sectional population-based study carried out using the same methodology in all its centres. The main objective of the EISL is to determine the prevalence of RW and related characteristics in the first year of life (defined as three or more parent-reported wheezing episodes during that time) and to compare it between centres. It uses a standardised questionnaire on wheezing that also includes questions on common cold or upper respiratory tract infection (URTI), treatment modalities such as inhaled bronchodilators (BD), inhaled corticosteroids (ICS) and leukotriene receptor antagonists (LTRA), severe episodes, sleep disturbance, emergency department (ED) visits and admissions to hospital due to wheezing, among others. For questions on URTI, parents were asked if their babies had had acute episodes of common cold with runny nose (watery nasal rhinorrhea), sneezing, nasal obstruction, mild cough, with or without mild fever. A parental history of asthma was defined as a positive response to the question on maternal or paternal asthma. The questions on wheezing had been previously validated in physician-diagnosed wheezing (general paediatricians and paediatric pulmonologists) in centres in Latin
Paediatric lung disease

America and Spain.\textsuperscript{11,12} The Portuguese version of the questionnaire was translated from Spanish into Portuguese and back-translated from Portuguese into Spanish. The same was done with the Dutch version.

The methodology used in the EISL was partially based on that employed in phases I and III by the International Study of Asthma and Allergies in Childhood (ISAAC).\textsuperscript{13,14}—that is, random samples, centres in different countries, same methods and questionnaire used by the different participating centres and study supervised by local and national coordinators. The centres that participated in the present study also participated in either ISAAC phase I or III, or both.

The study samples were drawn from the populations living in defined geographical areas (centres) from Latin America (LA), Spain and The Netherlands through scientific networks and focusing on locations of particular interest. A centre in The Netherlands was included for comparison with Spanish centres and, although ethnically different, the European (EU) centres participating in this study share similar high cultural and socioeconomic development and thus can be considered as representatives of fully-developed and well-resourced western countries. Each collaborating centre was responsible for completing a registration document and obtaining its own funding.

The sample size was calculated with reference to RW rather than to the prevalence of one or more episodes of wheezing. If the real prevalence of RW in the first year of life is 20% in one centre and 15% in another, samples of approximately 1000 individuals per centre would have an 80% power to detect a true difference at a significance level of 5%. This number was therefore the sample size sought in each centre.

Subjects and sampling frame

All the primary care health clinics where infants attend for growth/development monitoring and/or vaccine administration, according to the national public health programmes in each country, and located in the geographical area corresponding to an EISL centre were considered for recruiting infants and their parents or guardians. A random sample of those centres was selected providing they could recruit at least 1000 children aged 12–15 months at the time of responding to the questionnaires. Parents or guardians were asked to complete the questionnaire when infants were brought for a scheduled vaccine administration or a preventive healthcare visit at that age, emphasising that questions were only related to events that had occurred during the first 12 months of life of their children and without assistance from centre staff.

In order to test the effect of two different viral seasons, four centres planned their fieldwork to be extended to two consecutive years so they had approximately half of the sample in each year.

Centres performed the survey between March 2005 and March 2007 and those which provided a clean data set by the end of 2007 were included in the present report.

Data analysis

Data from the different participating centres were analysed by SPSS V.13. Descriptive statistics, including 95% CIs, were employed to show the differences between centres and between groups of centres within countries or regions. Crude ORs were used to estimate the strength of the wheezing-related factors in LA and EU. The \( \chi^2 \) test was used to assess the significance of associations and differences between proportions; \( p<0.05 \) was considered statistically significant.

The results are expressed as mean (95% CI) except for age which is reported as mean±SD.

RESULTS

There were 17 official EISL centres which supplied 30 093 correctly completed questionnaires (25 030 from 12 centres in Latin America and 5063 from 5 centres in Europe). The mean response rate was 83.2%. The mean age for the whole sample of infants (47.5% female) was 13.4±1.7 months; 13.3±1.3 months in LA and 14.5±3.0 months in EU. The proportion of questionnaires filled out by mothers was 86.5%, by fathers was 5.8% and by guardians was 7.7%.

In the whole sample (all the participating infants from LA and EU) it was found that 45.2% (95% CI 44.7% to 45.8%) wheezed at least once during their first year of life; 20.3% (95% CI 20.8% to 21.7%) had RW; 8.5% (95% CI 8.2% to 8.8%) reported physician-diagnosed asthma; and 16.7% (95% CI 16.5% to 17.2%) of infants had their first episode of wheezing during the first 3 months of life. The prevalence of RW in LA varied from 2.3% in Merida (Mexico) to 55.3% in Porto Alegre (Brazil), while in the EU centres it ranged from 12.1% in Valencia (Spain) to 18.6% in Bilbao (Spain). There was a high variability between centres with respect to the prevalence of RW, physician-diagnosed asthma, severity of wheezing episodes, admissions to hospital due to wheezing and the other related variables both in centres within the same country and between countries. Two centres (Fortaleza and Recife) could not provide data on the prevalence of parental asthma (table 1).

There was a significant association between having an URTI in the first 3 months of life and wheezing in the same period, and also with RW later. The proportion of infants who had an URTI during the first 3 months of life was significantly higher in LA (58.2%, 95% CI 57.6% to 58.8%) than in EU (30.0%, 95% CI 28.7% to 31.3%). Parental history of asthma was reported in 16.6% (95% CI 16.2% to 17.1%) of infants, and was significantly larger in LA (18.2%, 95% CI 17.7% to 18.7%) than in EU (10.2%, 95% CI 9.4% to 11.0%). Reported physician-diagnosed asthma was also significantly higher in LA (9.20%, 95% CI 8.9% to 9.6%) than in EU centres (4.70%, 95% CI 4.2% to 5.4%). The proportion of infants with RW and reported eczema was significantly higher in LA (56.9%, 95% CI 56.0% to 57.8%) than in EU (20.2%, 95% CI 18.4% to 22.2%).

The prevalence of the severity markers of wheezing (severe episodes, visits to ED and hospital admissions) was significantly lower in EU than in LA (table 1), and this difference was even greater when comparing only infants with RW (table 2).

When considering only infants with RW (figure 1), there were also large differences between LA and EU centres—and also within the same countries—regarding use of medications, prevalence of URTI in the first 3 months of life, parental history of asthma, physician-diagnosed asthma, severe episodes and use of health resources (table 2). The reported use of ICS in infants with RW during the first year of life was 46.1% in the entire population, but it was significantly lower in LA centres (45.0%, 95% CI 45.6% to 46.3%) than in EU (54.2%, 95% CI 50.5% to 57.9%). There was no significant difference between LA and EU in the proportion of infants with RW who had been admitted to hospital and who received ICS (65.5%, 95% CI 63.0% to 67.9% vs 70.2%, 95% CI 61.4% to 79.7%), nor for those who received other medications (BD and LTRA). In the whole sample, the proportion of infants who used ICS was significantly higher in those who had severe episodes (OR 11.80, 95% CI 11.76 to 12.64), frequent sleep disturbance (OR 5.85, 95% CI 5.35 to 6.42), visits to the ED (OR 11.81, 95% CI 10.97 to 12.70) and...
admissions (OR 10.85, 95% CI 9.93 to 11.86) compared with those who did not have these wheezing severity indices. In infants with RW, the use of ICS was also significantly higher in those who had severe episodes (OR 2.27, 95% CI 2.03 to 2.53), frequent sleep disturbance (OR 1.38, 95% CI 1.22 to 1.55), visits to the ED (OR 2.27, 95% CI 2.03 to 2.53), and admissions due to wheezing (OR 10.85, 95% CI 9.93 to 11.86) compared with those who did not have these severe episodes.

In centres where prescribing ICS has no or minimal cost for parents, the percentage of infants with RW who had visited the ED and had received ICS was not significantly higher in EU (61.5%, 95% CI 56.4% to 66.3%) than in LA (56.1%, 95% CI 54.3% to 58.0%) whereas in centres where ICS were not available (table 2) the percentage was significantly lower (28.7%, 95% CI 25.9% to 31.6%). A physician diagnosis of asthma was reported in 25.9% of all infants with RW (26.5% in LA and 24.6% in EU) and the use of ICS was also significantly higher in LA (41.7%) than in those with RW but without a diagnosis of asthma (67.9%). Also, there was a significantly higher proportion of hospital admissions in infants with RW and an asthma diagnosis (41.7%) than in those without an asthma diagnosis (22.0%).

The prevalence of wheezing-related factors was significantly higher in LA than in EU. The associations between several factors and children from LA centres compared with EU centres (base) are shown in table 3.

In the four centres (two from LA and two from EU) where the prevalence of RW between two consecutive years (two viral seasons) was assessed, it was found that the difference was significant: 1.5% in Cartagena (Spain); 0.6% in Zwolle (The Netherlands); 1.3% in Santiago (Chile); and 2.9% in Curitiba (Brazil).

**DISCUSSION**

This first international comparison of the prevalence of RW during the first year of life found a high prevalence of this condition, with a large variability among centres and lower prevalence and severity in EU than in LA centres. This study also found a high proportion of infants with RW whose condition was severe, as reflected by sleep disturbance, severe episodes, ED visits and admissions to hospital. This is the first time that this type of information is available at an international level,
including infants from centres in countries with different cultural and socioeconomic levels.

The high proportion of ED visits and hospital admissions due to wheezing, severe episodes and frequent sleep disturbance reported by parents of infants with RW in centres in LA and EU suggests a rather poor management of infants with troublesome RW, as found by previous studies in wheezy young children. Although the role of ICS in infants with RW is controversial, with reported benefits in infants with multiple trigger wheeze but little effect in episodic viral wheeze, this study shows that ICS are commonly prescribed to even the youngest infants.

There is consistent evidence to support the concept that viral respiratory infections by common respiratory viruses are able to induce immunological changes significantly related with a higher risk of RW during the first year of life. Furthermore, symptomatic rhinovirus illness during infancy is a significant risk factor for the development of preschool RW and asthma, and is frequently reported in infants with RW during the first months and triggered by different factors. There is a higher risk of RW during the first year of life, and there is a significant relation with personal eczema and a parental history of asthma.

Although a parental history of asthma and of personal eczema are significant risk factors for RW later during the first year of life, no more than 40% of those infants were diagnosed with asthma although both conditions are mentioned as a response favouring RW or simply reveal a genetic predisposition to this condition, or both.

Although the role of ICS in infants with RW is controversial, with reported benefits in infants with multiple trigger wheeze but little effect in episodic viral wheeze, this study shows that ICS are commonly prescribed to even the youngest infants with wheeze.
important elements to make the diagnosis of asthma in infants with repeated asthma-like symptoms.22–24

Low socioeconomic status has been shown to be a risk factor for persistent respiratory problems in infants such as wheezing and pneumonia6,25 and could be an important determinant for the lower prevalence and severity of RW in infants from EU centres compared with those from LA. However, the differences in the prevalence and severity of RW in infants within and between countries are probably due to complex and multifactorial environment—gene interactions that are distinctive for each locality and capable of modulating the airway responses from very early in life through to adulthood.

The very low and high prevalence of RW found in Merida (Mexico) (2.3%) and Porto Alegre (Brazil) (56.3%) cannot be satisfactorily explained by cross-sectional studies such as this one. It may be that local cultural, genetic and environmental risk/protective factors as well as methodological issues (low comprehension of questions by an important number of parents) are responsible for these findings. However, infants in Merida (Mexico) and Porto Alegre (Brazil) might genuinely represent the lower and upper range of the prevalence distribution spectrum of RW in the region, but this needs to be confirmed by further studies.

Apart from the limitations inherent to all cross-sectional studies, the present study in infants during the first year of life has the potential limitation of using a parental report instead of a physician’s report. However, parental report of wheezing versus clinical examination was previously validated in infants from LA attending an ED with acute wheezing episodes,12 and also against examination by a paediatric thoracic physician and clinical records in infants with RW exacerbations followed up in specialised units in LA and Spain.11 The present study could not include centres from Portugal to compare with centres from Brazil; however, the prevalence of asthma in children from the Iberian Peninsula (Spain and Portugal) is very similar.9,10 The effect of an eventual yearly variation of the viral season (autumn–winter) on the prevalence of RW may also be considered as a limitation. Nevertheless, the difference found in this regard was quite small and non-significant. The latter would also support the consistency of the methodology used.

The strengths of the present study include its population-based sampling strategy, large sample size, relatively high response rate and the inclusion of centres with different cultural and socioeconomic levels, thus making the results representative of the participating countries and regions. In addition, the EISL provides previously lacking comparative epidemiological information on RW during the first year of life on an international scale. The parent-reported information on wheezing occurring during the first year of life of the infants and collected when the infants were aged 12–15 months may decrease the chance of maternal recall bias in this study.

Our results suggest that there is room for improvement in the implementation of efficient strategies for the education and management of RW directed to parents and health personnel. It is likely that increasing the awareness of identifying and managing infants with RW, especially those with troublesome symptoms, may result in a decrease in the prevalence of severe episodes, visits to the ED and admissions to hospital.

In conclusion, the present study shows that the prevalence of RW during the first year of life is high in most centres and significantly variable, with a clear trend to be higher and more severe in LA than in EU. In spite of the high prevalence of RW, visits to the ED and admissions to hospital due to wheezing, a relatively infrequent use of ICS in infants with severe disease was reported in a considerable proportion of those infants. The present findings cast some doubts on the ‘benign’ course and presentation of RW during the first year of life in both affluent and non-affluent countries, and suggest the need for changes in the current approach to the diagnosis and management of RW in order to improve the important deleterious effect of this condition on the quality of life of infants and parents.

Acknowledgements We are grateful to the parents who participated with their infants in the International Study of Wheezing in Infants (EISL); the collaboration and assistance provided by the staff of the Primary Care Health centres; and Mr Anthony Carlson for his correction of the English language of this paper.

EISL Study Group Manuel Baeza-Bacab, (Mexico, Mérida); Álvaro Madeiro Leite, Olivia Costa Bessa (Brazil, Fortaleza); Elaine Xavier Prestes (Brazil, Belém); Emanuel Sarinho, Décor Medeiros (Brazil, Recife); Paulo Carneiro, Maria Jussara Fernández-Fontes, Wilson Rocha (Brazil, Bello Horizonte); Dicrue Solé, Caroine Della Bianca (Brazil, São Paulo); Nelson Rosario Herberto Chong (Brazil, Curitiba); Gilberto B Fischer (Brazil, Porto Alegre); Eduardo Cepeda (Colombia, Barranquilla); Oscar Aldrey, Arnaldo Capiles (Venezuela, Caracas); Javier Mañol, Viviana Aguille, Alejandro Gallardo (Chile, Santiago); Mario Calvo (Chile, Valdivia); Luis García-Marcos, Antoneila Martínez-Torres, Virginia Pérez-Fernández, (España, Murcia); Carlos González-Blázquez, Andrés González-Hermosa (España, Bilbao); Ángel López-Silvarrey Varela (España, La Coruña); María Morales Suárez-Varela (España, Valencia); Paul L P Brand, Chantal A N Visser (Zwolle, The Netherlands).

Competing interests None.

Patient consent Parents or guardians who agreed to participate in the study filled in the questionnaire after reading and signing a fully informed written consent form.

Ethics approval This study was conducted with the approval of the Scientific Ethics Committee, Chilean Ministry of Health, Southern Metropolitan Area of Santiago de Chile (Chile), the Ethics Committee of the University of Murcia (Spain) for all Spanish

<table>
<thead>
<tr>
<th>Table 3 Wheezing-related factors for Latin American centres versus European centers (base)</th>
<th>Crude OR (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole sample</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wheezing once or more</td>
<td>1.71 (1.61 to 1.83)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Recurrent wheezing</td>
<td>1.55 (1.43 to 1.69)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>URTI first 3 months of life</td>
<td>1.43 (1.34 to 1.53)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Wheezing first 3 months of life</td>
<td>1.87 (1.69 to 2.05)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Parental history of asthma</td>
<td>1.94 (1.76 to 2.14)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Physician-diagnosed asthma</td>
<td>2.05 (1.79 to 2.35)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Eczema</td>
<td>5.48 (5.05 to 5.96)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Inhaled bronchodilator</td>
<td>1.88 (1.75 to 2.01)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Inhaled corticosteroids</td>
<td>1.03 (0.95 to 1.27)</td>
<td>0.48</td>
</tr>
<tr>
<td>Leukotriene receptor antagonist</td>
<td>0.52 (0.46 to 0.59)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hospital admission due to wheezing</td>
<td>2.76 (2.38 to 3.19)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>ED visit due to wheezing</td>
<td>2.03 (1.87 to 2.19)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Severe wheezing episode</td>
<td>2.12 (1.94 to 2.32)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Frequent sleep disturbance due to wheezing</td>
<td>1.89 (1.65 to 2.17)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Recurrent wheezing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>URTI first 3 months of life</td>
<td>1.39 (1.19 to 1.62)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Wheezing first 3 months of life</td>
<td>1.59 (1.36 to 1.87)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Parental history of asthma</td>
<td>1.89 (1.46 to 2.42)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Physician-diagnosed asthma</td>
<td>1.35 (1.23 to 1.63)</td>
<td>0.0014</td>
</tr>
<tr>
<td>Eczema</td>
<td>4.75 (3.98 to 5.66)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Inhaled bronchodilator</td>
<td>4.17 (3.41 to 5.10)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Inhaled corticosteroids</td>
<td>0.68 (0.58 to 0.79)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Leukotriene receptor antagonist</td>
<td>0.45 (0.37 to 0.56)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hospital admission due to wheezing</td>
<td>2.43 (1.96 to 3.01)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>ED visit due to wheezing</td>
<td>2.29 (1.96 to 2.68)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Severe wheezing episode</td>
<td>1.95 (1.67 to 2.28)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Frequent sleep disturbance due to wheezing</td>
<td>1.81 (1.49 to 2.19)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

ED, emergency department; URTI, upper respiratory tract infection.
centres, and the respective Ethics Committees for the rest of the participating centres.

Provenance and peer review  Not commissioned; externally peer reviewed.

REFERENCES
International prevalence of recurrent wheezing during the first year of life: variability, treatment patterns and use of health resources

Javier Mallol, Luis García-Marcos, Dirceu Solé, Paul Brand and the EISL Study Group

*Thorax* published online September 20, 2010

Updated information and services can be found at:
http://thorax.bmj.com/content/early/2010/09/20/thx.2009.115188

**References**

This article cites 22 articles, 6 of which you can access for free at:
http://thorax.bmj.com/content/early/2010/09/20/thx.2009.115188#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Epidemiologic studies (1829)
- Child health (843)
- Infant health (48)
- Drugs: respiratory system (526)
- General practice / family medicine (339)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/